COVID-19 myocarditis and prospective heart failure burden

References

• World Health Organization. Coronavirus disease 2019 (COVID-19): situation reports. July 1, 2020. [Internet]. [cited 2020 Jul]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200701-covid-19-sitrep-163.pdf?sfvrsn=c202f05b_2
   Google Scholar
• Shi S, Qin M, Shen B, et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–810.
   PubMed Web of Science ®Google Scholar
• Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–818.
   PubMed Web of Science ®Google Scholar
• Teuwen LA, Geldhof V, Pasut A, et al. COVID-19: the vasculature unleashed. Nature Reviews Immunology. Nat Res. 2020;20(7):389–391.
   Google Scholar
• Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 May 2;395(10234):1417–1418.
   PubMed Web of Science ®Google Scholar
• Shi S, Qin M, Cai Y, et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020 Jun 7;41(22):2070–2079.
   PubMed Web of Science ®Google Scholar
• Tavazzi G, Pellegrini C, Maurelli M, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020 May;22(5):911–915.
   PubMed Web of Science ®Google Scholar
• Schaller T, Hirschbühl K, Burkhardt K, et al. Postmortem Examination of Patients with COVID-19. JAMA. 2020 Jun 23;323(24):2518–2520.
   PubMed Web of Science ®Google Scholar
• Ammirati E, Cipriani M, Moro C, et al. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis multicenter Lombardy registry. Circulation. 2018;138(11):1088–1099.
   PubMed Web of Science ®Google Scholar
• Grun S, Schumm J, Greulich S, et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012 May 1;59(18):1604–1615.
   PubMed Web of Science ®Google Scholar
• Gutberlet M, Spors B, Thoma T, et al. Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence. Radiology. 2008 Feb;246(2):401–409.
   PubMed Web of Science ®Google Scholar
• Spieker M, Haberkorn S, Gastl M, et al. Abnormal T2 mapping cardiovascular magnetic resonance correlates with adverse clinical outcome in patients with suspected acute myocarditis. J Cardiovasc Magn Reson. 2017 Mar 29;19(1):38.
   PubMedGoogle Scholar
• Felker GM, Hu W, Hare JM, et al. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. Medicine (Baltimore). 1999 Jul;78(4):270–283.
   PubMed Web of Science ®Google Scholar
• Caforio ALP, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J Eur Heart J. 2007 Jun;28(11):1326–1333.
   PubMed Web of Science ®Google Scholar
• Lala A, Johnson KW, Januzzi JL, et al. Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection. Preprint. 2020 Apr 24. [ medRxiv. 2020;2020.04.20.20072702. Published]. DOI:10.1101/2020.04.20.20072702.
   Google Scholar
• Kermali M, Khalsa RK, Pillai K, et al. The role of biomarkers in diagnosis of COVID-19 - A systematic review. Life Sci. 2020;254:117788.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. Intensive Care Med. 2020 May;46(5):846–848.
   PubMed Web of Science ®Google Scholar
• Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27;5(7):1–6.
   Web of Science ®Google Scholar
• Kim IC, Kim JY, Kim HA, et al. COVID-19-related myocarditis in a 21-year-old female patient. Eur Heart J. 2020 May 14;41(19):1859.
   PubMed Web of Science ®Google Scholar
• Khambekar S, Harden S, Corbett S. Influenza A (H1N1) and myocarditis. Heart. 2011 Oct;97(19):1630.
   PubMed Web of Science ®Google Scholar
• Jain S, Kamimoto L, Bramley AM, et al. Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009. N Engl J Med. 2009 Nov 12;361(20):1935–1944.
   PubMed Web of Science ®Google Scholar
• Yu CM, Wong RSM, Wu EB, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006 Feb;82(964):140–144.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhao P, Tang D, et al. Cardiac involvement in recovered COVID-19 patients identified by magnetic resonance imaging. J Am Coll Cardiol Img. 2020 Aug 05. Epublished. DOI:10.1016/j.jcmg.2020.05.004.
   Google Scholar
• Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 July 27. Published online. DOI:10.1001/jamacardio.2020.3557.
   Web of Science ®Google Scholar
• Pollack A, Kontorovich AR, Fuster V, et al. Viral myocarditis-diagnosis, treatment options, and current controversies. Nat Rev Cardiol. 2015 Nov;12(11):670–680.
   PubMed Web of Science ®Google Scholar
• Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020 May 9;395(10235):1517–1520.
   PubMed Web of Science ®Google Scholar
• Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009 Jul;39(7):618–625.
   PubMed Web of Science ®Google Scholar
• Lindner D, Fitzek A, Bräuninger H, et al. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA Cardiol. 2020 July 27. [ Published online]. DOI:10.1001/jamacardio.2020.3551.
   PubMed Web of Science ®Google Scholar
• Malavazos AE, Goldberger JJ, Iacobellis G. Does epicardial fat contribute to COVID-19 myocardial inflammation? Eur Heart J. 2020;41(24):2333.
   PubMed Web of Science ®Google Scholar
• Rey JR, Caro-Codón J, Rosillo SO, et al. Heart Failure In Covid-19 Patients: prevalence, Incidence And Prognostic Implications. Eur J Heart Fail. 2020. DOI:10.1002/ejhf.1990.
   Web of Science ®Google Scholar
• Elamm C, Fairweather DL, Cooper LT. Pathogenesis and diagnosis of myocarditis. Heart. 2012 Jun;98(11):835–840.
   PubMed Web of Science ®Google Scholar
• Myers JM, Cooper LT, Kem DC, et al. Cardiac myosin-Th17 responses promote heart failure in human myocarditis. JCI Insight. 2016 Jun 16;1(9):e85851.
   PubMed Web of Science ®Google Scholar
• Sanguineti F, Garot P, Mana M, et al. Cardiovascular magnetic resonance predictors of clinical outcome in patients with suspected acute myocarditis. J Cardiovasc Magn Reson. 2015 Aug 29;17(1):78.
   PubMedGoogle Scholar
• Gräni C, Eichhorn C, Bière L, et al. Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis. J Am Coll Cardiol. 2017 Oct 17;70(16):1964–1976.
   PubMed Web of Science ®Google Scholar
• Aquaro GD, Ghebru Habtemicael Y, Camastra G, et al. Prognostic Value of Repeating Cardiac Magnetic Resonance in Patients With Acute Myocarditis. J Am Coll Cardiol. 2019 Nov 19;74(20):2439–2448.
   PubMed Web of Science ®Google Scholar
• Hinojar R, Foote L, Ucar EA, et al. PNative T1 in discrimination of acute and convalescent stages in patients with clinical diagnosis of myocarditis: a proposed diagnostic algorithm using CMR. JACC Cardiovasc Imaging. 2015;8(1):37–46.
   Google Scholar
• Von Knobelsdorff-Brenkenhoff F, Schüler J, Dogangüzel S, et al. Detection and Monitoring of Acute Myocarditis Applying Quantitative Cardiovascular Magnetic Resonance. Circ Cardiovasc Imaging. 2017 Feb;10(2):e005242.
   PubMed Web of Science ®Google Scholar
• Bohnen S, Radunski UK, Lund GK, et al. Performance of T1 and T2 Mapping Cardiovascular Magnetic Resonance to Detect Active Myocarditis in Patients with Recent-Onset Heart Failure. Circ Cardiovasc Imaging. 2015 Jun;8(6):e003073.
   PubMed Web of Science ®Google Scholar
• Wong TC, Piehler KM, Kang JA, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J. 2014 Mar;35(10):657–664.
   PubMed Web of Science ®Google Scholar
• Schelbert EB, Piehler KM, Zareba KM, et al. Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage. J Am Heart Assoc. 2015 Dec 18;4(12):e002613.
   PubMed Web of Science ®Google Scholar
• Schelbert EB, Fridman Y, Wong TC, et al. Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baseline disease severity and subsequent outcome. JAMA Cardiol. 2017 Sep 1;2(9):995–1006.
   PubMed Web of Science ®Google Scholar
• Frantz S, Falcao-Pires I, Balligand JL, et al. The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. Eur J Heart Fail. 2018 Mar;20(3):445–459.
   PubMed Web of Science ®Google Scholar
• Hinojar R, Foote L, Sangle S, et al. Native T1 and T2 mapping by CMR in lupus myocarditis: disease recognition and response to treatment. Int J Cardiol. 2016 Nov 1;222:717–726.
   PubMed Web of Science ®Google Scholar
• Puntmann VO, D’Cruz D, Smith Z, et al. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circ Cardiovasc Imaging. 2013;6(2):295–301.
   PubMed Web of Science ®Google Scholar
• Markousis-Mavrogenis G, Koutsogeorgopoulou L, Katsifis G, et al. The double-edged sword of t1-mapping in systemic sclerosis-a comparison with infectious myocarditis using cardiovascular magnetic resonance. Diagnostics (Basel). 2020 May;10(5):335.
   Google Scholar
• Ntusi NA, Piechnik SK, Francis JM, et al. Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis - A clinical study using myocardial T1-mapping and extracellular volume quantification. J Cardiovasc Magn Reson. 2014 Mar 4;16(1):21.
   PubMedGoogle Scholar
• Mueller KAL, Mueller II, Eppler D, et al. Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy. PLoS One. 2015 May 12;10(5):e0126707.
   PubMed Web of Science ®Google Scholar
• Prasada S, Rivera A, Nishtala A, et al. Differential Associations of Chronic Inflammatory Diseases With Incident Heart Failure. JACC Heart Fail. 2020 Jun 1;8(6):489–498.
   PubMed Web of Science ®Google Scholar
• Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016 Sep 21;37(36):2768–2801.
   Google Scholar
• Čelutkienė J, Pudil R, López‐Fernández T, et al. The role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a Position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020 Jul 4. DOI:10.1002/ejhf.1957.
   Google Scholar
• Moslehi JJ Cardiovascular toxic effects of targeted cancer therapies. Vol. 375, New England Journal of Medicine. Massachusetts Medical Society; 2016. p. 1457–1467.
   Google Scholar
• Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the Setting of Cancer Therapeutics: proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation. 2019 Jul 2;140(1):80–91.
   PubMed Web of Science ®Google Scholar
• Galán-Arriola C, Lobo M, Vílchez-Tschischke JP, et al. Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity. J Am Coll Cardiol. 2019 Feb 26;73(7):779–791.
   PubMed Web of Science ®Google Scholar
• Haslbauer JD, Lindner S, Valbuena-Lopez S, et al. CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping. Int J Cardiol. 2019 Jan 15;275:179–186.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015 Jun 2;131(22):1981–1988.
   PubMed Web of Science ®Google Scholar
• Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016 Jun 1;37(21):1671–1680.
   PubMed Web of Science ®Google Scholar
• Díez J, Querejeta R, López B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. Circulation. 2002 May 28;105(21):2512–2517.
   PubMed Web of Science ®Google Scholar
• Izawa H, Murohara T, Nagata K, et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation. 2005 Nov 8;112(19):2940–2945.
   PubMed Web of Science ®Google Scholar
• López B, Querejeta R, González A, et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004 Jun 2;43(11):2028–2035.
   PubMed Web of Science ®Google Scholar
• Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. Circulation. 2000 Sep 19;102(12):1388–1393.
   PubMed Web of Science ®Google Scholar
• Zile MR, O’Meara E, Claggett B, et al. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. J Am Coll Cardiol. 2019;73(7):795–806.
   PubMed Web of Science ®Google Scholar
• Tschöpe C, Van Linthout S, Jäger S, et al. Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis. ESC Hear Fail. [Internet]. 2020 Jul;14:ehf2.12887.
   Google Scholar
• Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2013 Sep 7;34(33):2636–2648.
   PubMed Web of Science ®Google Scholar
• Lurz P, Eitel I, Adam J, et al. Diagnostic Performance of CMR Imaging Compared With EMB in Patients With Suspected Myocarditis. 2012. JACC Cardiovasc Imaging. 2012 May 5;5:513–524.
   PubMed Web of Science ®Google Scholar
• Lurz P, Luecke C, Eitel I, et al. Comprehensive Cardiac Magnetic Resonance Imaging in Patients With Suspected Myocarditis The MyoRacer-Trial. Am Coll Cardiol. 2016 Apr 19;67(15):1800–1811.
   PubMed Web of Science ®Google Scholar
• Puntmann VO, Zeiher AM, Nagel E. T1 and T2 mapping in myocarditis: seeing beyond the horizon of Lake Louise criteria and histopathology. Expert Rev Cardiovasc Ther. 2018 May;16(5):319–330.
   PubMed Web of Science ®Google Scholar
• Radunski UK, Lund GK, Stehning C, et al. CMR in Patients With Severe Myocarditis Diagnostic Value of Quantitative Tissue Markers Including Extracellular Volume Imaging. 2014. JACC Cardiovasc Imaging. 2014 Jul 7;7:667–675.
   PubMed Web of Science ®Google Scholar
• Gulati A, Jabbour A, Ismail TF, et al. Association of Fibrosis With Mortality and Sudden Cardiac Death in Patients With Nonischemic Dilated Cardiomyopathy. JAMA. 2013 Mar 6;309(9):896–908.
   PubMed Web of Science ®Google Scholar
• Puntmann VO, Valbuena S, Hinojar R, et al. Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part i - Analytical validation and clinical qualification. J Cardiovasc Magn Reson. 2018 Sep 20;20(1):67.
   PubMedGoogle Scholar
• Hinojar R, Foote L, Cummins C, et al. Standardised postprocessing of native T2 in detection and discrimination of myocarditis - comparison with native T1 mapping. J Cardiovasc Magn Reson. 2016;18(Suppl1):O14.
   Google Scholar
• Puntmann VO, Peker E, Chandrashekhar Y, et al. T1 mapping in characterizing myocardial disease: a comprehensive review. Circ Res. 2016 Jul 8;119(2):277–299.
   Google Scholar
• Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation. J Am Coll Cardiol. 2018 Dec;72(24):3158–3176.
   PubMed Web of Science ®Google Scholar
• Lurz JA, Luecke C, Lang D, et al. CMR–Derived Extracellular Volume Fraction as a Marker for Myocardial Fibrosis: the Importance of Coexisting Myocardial Inflammation. JACC Cardiovasc Imaging. 2018;11(1):38–45. 72.
   PubMed Web of Science ®Google Scholar
• Hinojar R, Foote L, Ucar EA, et al. Native T1 in discrimination of acute and convalescent stages in patients with clinical diagnosis of myocarditis: a proposed diagnostic algorithm using CMR. JACC Cardiovasc Imaging. 2015;8(1):37–46.
   PubMed Web of Science ®Google Scholar
• Wong TC, Piehler K, Meier CG, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012. Circulation. 2012 Sep 4;126(10):1206–1216.
   PubMed Web of Science ®Google Scholar
• Kammerlander AA, Marzluf BA, Zotter-Tufaro C, et al. T1 mapping by CMR imaging from histological validation to clinical implication. JACC Cardiovasc Imaging. 2016 Jan 1;9(1):14–23.
   PubMed Web of Science ®Google Scholar
• Winau L, Nagel E, Herrmann E, et al. Towards the clinical management of cardiac involvement in systemic inflammatory conditions—a central role for CMR. Curr Cardiovasc Imaging Rep. 2018;11:11.
   Web of Science ®Google Scholar